In results announced this morning, Enveric reported new mechanistic findings from proprietary bioluminescence resonance energy transfer, or BRET, assays evaluating its lead candidate, EB-003. The data show that EB-003 activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT2A receptor, a key molecular target associated with psychedelic compounds.

Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. EB-003 is being developed to be a non-hallucinogenic neuroplastogen intended to support streamlined treatment paradigms, including potential at-home administration.

For decades, psychedelics like psilocybin and N,N-dimethyltryptamine (DMT) have intrigued scientists and clinicians with their ability to rapidly reshape the brain and improve mental health. Clinical trials have shown promise for conditions ranging from depression and anxiety to post-traumatic stress disorder (PTSD), but there is still a potential downside.

The clean energy transition is often framed as an engineering story: better batteries, smarter grids, cheaper renewables. In reality, it is also a mining story, because electrification is metals-intensive. Solar, wind, transmission buildouts, EVs, and energy storage all rely on a steady stream of copper, nickel, cobalt, graphite, vanadium, and rare earth elements, many of […]

As the world grapples with climate change and environmental degradation, the shift towards renewable energy has never been more critical. Innovative companies are at the forefront of this transformation, developing sustainable energy solutions that reduce carbon footprints and promote a greener future. How are these companies driving the renewable energy revolution, and what impact are […]

North America’s shift toward renewable energy depends on a foundation that is often overlooked: secure access to critical metals. These minerals form the backbone of solar panels, wind turbines, advanced batteries, hydrogen systems, and electric vehicles. As demand accelerates, Canada has emerged as a central player in the strategy to build reliable, ethical, and resilient […]

As 2025 comes to an end, it’s a good moment to take a look at what happened this year in biotech. Unlike years defined by one big breakthrough, 2025 felt more like a phase shift, where many trends that had been building finally started to matter in practice.

Enveric Biosciences Inc (NASDAQ: ENVB) will soon have a patent in hand for its EVM301 non-psychoactive, psychedelic-inspired drugs. The United States Patent and Trademark Office just gave Enveric a notice of allowance, thereby signalling that the agency views the patent application favourably.

Enveric Biosciences (NASDAQ:ENVB) recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by rival Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276 (the ‘276 patent) titled, “Halogenated psilocybin derivatives and methods of using.”

For years, the psychedelic renaissance focused on one clear idea. If you could deliver a guided psychedelic experience safely and predictably, you could lift people out of stubborn depression, trauma, and addiction. That wave brought psilocybin, MDMA, ketamine clinics, and a flood of research interest. However, it was not adoptable by large patient bases.